Opportunistic infections with anti-tumor necrosis factor-α therapy in inflammatory bowel disease: Meta-analysis of randomized controlled trials

American Journal of Gastroenterology

Volumn 108, Issue 8, 2013, Pages 1268-1276

  Ford, Alexander C ^a,b   Peyrin Biroulet, Laurent ^c  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c UNIVERSITY HOSPITAL OF NANCY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; GOLIMUMAB; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; PLACEBO; TUMOR NECROSIS FACTOR ANTIBODY;

ARTICLE; CROHN DISEASE; CYTOMEGALOVIRUS INFECTION; DRUG EXPOSURE; EPSTEIN BARR VIRUS INFECTION; ESOPHAGUS CANDIDIASIS; FOLLOW UP; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; INFECTION RISK; META ANALYSIS; MILIARY TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NOCARDIOSIS; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); THRUSH; TREATMENT DURATION; ULCERATIVE COLITIS;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; HUMANS; INFLAMMATORY BOWEL DISEASES; OPPORTUNISTIC INFECTIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84881187537     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2013.138     Document Type: Article

References (55)

1. Braegger CP, Nicholls S, Murch SH et al. Tumour necrosis factor alpha in stool as a marker of intestinal infl ammation. Lancet 1992;339:89-91.
2. MacDonald TT, Hutchings P, Choy MY et al. Tumour necrosis factoralpha and interferon-gamma production measured at the single cell level in normal and infl amed human intestine. Clin Exp Immunol 1990 ; 81:301-5.
3. Breese EJ, Michie CA, Nicholls SW et al. Tumor necrosis factor alphaproducing cells in the intestinal mucosa of children with infl ammatory bowel disease. Gastroenterology 1994;106:1455-66.
4. Murch SH, Lamkin VA, Savage MO et al. Serum concentrations of tumour necrosis factor alpha in childhood chronic infl ammatory bowel disease. Gut 1991;32:913-7.
5. Watkins PE, Warren BF, Stephens S et al. Treatment of ulcerative colitis in the cottontop tamarin using antibody to tumour necrosis factor alpha. Gut 1997;40:628-33.
6. Akobeng AK, Zachos M. Tumour necrosis factor-alpha antibody for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2004 CD003574.
7. Rahimi R, Nikfar S, Abdollahi M. Do anti-tumour necrosis factors induce response and remission in patients with refractory Crohn's disease? A systematic meta-analysis of controlled clinical trials. Biomed Pharmacother 2007;61:75-80.
8. Shao L-M, Chen M-Y, Chen Q-Y et al. Meta-analysis: the effi cacy and safety of certolizumab pegol in Crohn's disease. Aliment Pharmacol Ther 2009;29:605-14.
9. Peyrin-Biroulet L, Deltenre P, de Suray N et al. Effi cacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebocontrolled trials. Clin Gastroenterol Hepatol 2008;6:644-53.
10. Gisbert JP, Gonzalez-Lama Y, Mate J. Systematic review: infl iximab therapy in ulcerative colitis. Aliment Pharmacol Ther 2007;25:19-37.
11. Lawson MM, Th omas AG, Akobeng AK. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2006 CD005112.
12. Rahimi R, Nikfar S, Abdollahi M. Meta-analysis technique confi rms the eff ectiveness of anti-TNF-in the management of active ulcerative colitis when administered in combination with corticosteroids. Med Sci Monit 2007;13:13-8.
13. Behm BW, Bickston SJ. Tumour necrosis factor-alpha antibody for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2008 CD006893.
14. Ford AC, Sandborn WJ, Khan KJ et al. Effi cacy of biological therapies in infl ammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011;106:644-59.
15. Kotlyar DS, Osterman MT, Diamond RH et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with infl ammatory bowel disease. Clin Gastroenterol Hepatol 2011;9:36-41.
16. Toruner M, Loft us EV Jr, Harmsen WS et al. Risk factors for opportunistic infections in patients with infl ammatory bowel disease. Gastroenterology 2008;134:929-36.
17. Keane J, Gershon S, Wise RP et al. Tuberculosis associated with infl iximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104.
18. Lichtenstein GR, Rutgeerts P, Sandborn WJ et al. A pooled analysis of infections, malignancy, and mortality in infl iximab-and immunomodulatortreated adult patients with infl ammatory bowel disease. Am J Gastroenterol 2012;107:1051-63.
19. Colombel J-F, Sandborn WJ, Panaccione R et al. Adalimumab safety in global clinical trials of patients with Crohn's disease. Infl amm Bowel Dis 2009;15:1308-19.
20. Lichtenstein GR, Feagan BG, Cohen RD et al. Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT ™ registry. Am J Gastroenterol 2012;107:1409-22.
21. Rahier JF, Ben-Horin S, Chowers Y, et al., European Crohn's and Colitis Organisation. European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in infl ammatory bowel disease. J Crohns Colitis 2009;3:47-91.
22. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions: Version 5.0.0. 2008. http://www.cochrane-handbook.org.
23. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88.
24. Higgins JPT, Th ompson SG, Deeks JJ. et al. Measuring inconsistency in meta-analyses. Br Med J 2003;327:557-60.
25. Egger M, Davey-Smith G, Schneider M et al. Bias in meta-analysis detected by a simple, graphical test. Br Med J 1997;315:629-34.
26. Sterne JA, Sutton AJ, Ioannidis JP et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. Br Med J 2011;343:d4002.
27. Colombel J-F, Sandborn WJ, Rutgeerts P et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007;132:52-65.
28. Colombel J-F, Sandborn WJ, Reinisch W, et al., for the SONIC Study Group. Infl iximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010;362:1383-95.
29. Hanauer SB, Feagan BG, Lichtenstein GR, et al., the ACCENT I Study Group. Maintenance infl iximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541-9.
30. Hanauer SB, Sandborn WJ, Rutgeerts P et al. Human anti-tumour necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006;130:323-33.
31. Jarnerot G, Hertervig E, Friis-Liby I et al. Infl iximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebocontrolled study. Gastroenterology 2005;128:1805-11.
32. Lemann M, Mary J-Y, Duclos B, et al., the Groupes D ' etudes Therapeutiques des Aff ections Infl ammatoires Digestives (GETAID). Infl iximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology 2006;130:1054-61.
33. Present DH, Rutgeerts P, Targan S et al. Infl iximab for the treatment of fi stulas in patients with Crohn's disease. N Engl J Med 1999;340:1398-405.
34. Probert CJ, Hearing SD, Schreiber S et al. Infl iximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut 2003;52:998-1002.
35. Regueiro M, Schraut W, Baidoo L et al. Infl iximab prevents Crohn's disease recurrence aft er ileal resection. Gastroenterology 2009;136 : 441-50.
36. Reinisch W, Sandborn WJ, Hommes DW et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011;60:780-7.
37. Rutgeerts P, D ' Haens G, Targan S et al. Effi cacy and safety of retreatment with anti-tumor necrosis factor antibody (infl iximab) to maintain remission in Crohn's disease. Gastroenterology 1999;117:761-9.
38. Rutgeerts P, Sandborn WJ, Feagan BG et al. Infl iximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005 ; 353:2462-76.
39. Sandborn W, Feagan B, Marano C et al. A phase 3 randomized, placebocontrolled, double-blind study to evaluate the safety and effi cacy of subcutaneous golimumab maintenance therapy in patients with moderately to severely active ulcerative colitis: Pursuit-maintenance. Am J Gastroenterol 2012;107 (Suppl 1s):S673-4.
40. Sandborn WJ, Feagan BG, Stoinov S, et al., for the PRECISE I Study Investigators. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007;357:228-38.
41. Sandborn WJ, Rutgeerts P, Enns R et al. Adalimumab induction therapy for Crohn disease previously treated with infl iximab: a randomized trial. Ann Intern Med 2007;146:829-38.
42. Sandborn WJ, Hanauer SB, Rutgeerts P et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007 ; 56:1232-9.
43. Sandborn WJ, Schreiber S, Feagan BG et al. Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial. Clin Gastroenterol Hepatol 2011;9:670-8.
44. Sandborn WJ, van Assche G, Reinisch W et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012;142:257-65.
45. Sands BE, Tremaine WJ, Sandborn WJ et al. Infl iximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Infl amm Bowel Dis 2001;7:83-8.
46. Sands BE, Anderson FH, Bernstein CN et al. Infl iximab maintenance therapy for fi stulizing Crohn's disease. N Engl J Med 2004;350:876-85.
47. Schreiber S, Rutgeerts P, Fedorak RN, et al., the CDP870 Crohn's Disease Study Group. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 2005;129:807-18.
48. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al., for the PRECISE 2 Study Investigators. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007;357:239-50.
49. Targan SR, Hanauer SB, van Deventer SJH et al. A short-term study of chimeric monoclonal antibody cA2 to tumour necrosis factor for Crohn's disease. N Engl J Med 1997;337:1029-35.
50. Watanabe M, Hibi T, Lomax KG, et al., Study Investigators. Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease. J Crohns Colitis 2012;6:160-73.
51. Winter TA, Wright J, Ghosh S et al. Intravenous CDP870, a pegylated Fab fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn's disease: an exploratory study. Aliment Pharmacol Ther 2004;20:1337-46.
52. Feagan BG, McDonald JW, Panaccione R et al. A randomized trial of methotrexate in combination with infl iximab for the treatment of Crohn's disease. Gastroenterology 2008;135:294-5.
53. D ' Haens G, Baert F, van Assche G, et al., for the Belgian Infl ammatory Bowel Disease Research Group and the North Holland Gut Club. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008;371:660-7.
54. Panaccione R, Ghosh S, Middleton S et al. Infl iximab, azathioprine, or infl iximab and azathioprine for treatment of moderate to severe ulcerative colitis: the UC SUCCESS trial. J Crohns Colitis 2011;5:S8.
55. Sandborn WJ, Feagan BG, Marano CW et al. A phase 2/3 randomized, placebo-controlled, double-blind study to evaluate the safety and effi cacy of subcutaneous golimumab induction therapy in patients with moderately to severely active ulcerative colitis: PURSUIT SC. Gastroenterology 2012;142 (Suppl 1):S161.